- Home
- KWR vs VRDN Comparison
KWR vs VRDN Comparison
Compare KWR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWR
- VRDN
- Stock Information
- Founded
- KWR 1918
- VRDN 2006
- Country
- KWR United States
- VRDN United States
- Employees
- KWR N/A
- VRDN N/A
- Industry
- KWR Major Chemicals
- VRDN Medical Specialities
- Sector
- KWR Industrials
- VRDN Health Care
- Exchange
- KWR Nasdaq
- VRDN Nasdaq
- Market Cap
- KWR 1.8B
- VRDN 1.6B
- IPO Year
- KWR 1985
- VRDN N/A
- Fundamental
- Price
- KWR $107.47
- VRDN $12.38
- Analyst Decision
- KWR Strong Buy
- VRDN Buy
- Analyst Count
- KWR 4
- VRDN 14
- Target Price
- KWR $157.75
- VRDN $36.82
- AVG Volume (30 Days)
- KWR 138.1K
- VRDN 808.7K
- Earning Date
- KWR 05-01-2025
- VRDN 05-06-2025
- Dividend Yield
- KWR 1.79%
- VRDN N/A
- EPS Growth
- KWR N/A
- VRDN N/A
- EPS
- KWR 5.29
- VRDN N/A
- Revenue
- KWR $1,812,841,000.00
- VRDN $302,000.00
- Revenue This Year
- KWR $3.06
- VRDN N/A
- Revenue Next Year
- KWR $5.01
- VRDN $21,976.14
- P/E Ratio
- KWR $20.47
- VRDN N/A
- Revenue Growth
- KWR N/A
- VRDN 4.86
- 52 Week Low
- KWR $95.91
- VRDN $9.90
- 52 Week High
- KWR $197.03
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- KWR 49.54
- VRDN 43.22
- Support Level
- KWR $99.18
- VRDN $11.76
- Resistance Level
- KWR $111.91
- VRDN $13.38
- Average True Range (ATR)
- KWR 3.55
- VRDN 0.75
- MACD
- KWR 1.56
- VRDN -0.00
- Stochastic Oscillator
- KWR 65.12
- VRDN 27.80
About KWR Quaker Houghton
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.